32 results about "Increased Coagulation Activity" patented technology

The novel amidino derivatives of the formula (I):wherein all the symbols are as in specification defined;have an inhibitory activity of a blood coagulation factor VIIa and are useful for treatment and / or prevention of several angiopathy caused by enhancing a coagulation activity, such as disseminated intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, peripheral arterial obstruction, thrombosis after artificial vascular transplantation and artificial valve transplantation, post-operative thrombosis, reobstruction and restenosis after coronary artery bypass operation, reobstruction and restenosis after PTCA or PTCR, thrombosis by extracorporeal circulation and procoagulative diseases such as glomerlonephriitis.

The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and / or prophylaxis of bleeding disorders, in particular hemophilia A and / or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.

The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain.

The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and / or prophylaxis of bleeding disorders, in particular hemophilia A and / or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.

The present invention relates to a high-activity blood coagulation factor XI mutant Ala570Thr (A570T), nucleotide sequences are shown as SEQ ID NO: 1-4 and an amino acid sequence is shown as SEQ ID NO: 5. A zymogen state is activated into an enzyme with activity to produce resistance of a physiological inhibitor, thus the high-activity blood coagulation factor XI mutant Ala570Thr has very high coagulation activity and stronger catalytic capability on a non-physiological substrate, is applied to treatments of hemorrhagic diseases, and has very good prospects for gene treatment, gene editing andrecombinant protein replacement.

The invention discloses a composition for improving the coagulation activity of a patient with type B hemophilia, a medicine and sgRNA (small guide Ribonucleic Acid), and relates to the field of genetreatment of hemophilia. The composition comprises a first AAV (Adeno-associated Virus) vector and a second AAV vector for expressing the sgRNA; a core sequence of the sgRNA is selected from SEQ ID NO. 6 to SEQ ID NO. 9. The composition can be used for treating the type B hemophilia and recovering the coagulation activity.

A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.

The invention relates to a method for detecting in a body fluid sample at least one blood coagulation activity marker that reflects the blood coagulation activity of an individual. By correlating the amount or concentration of the blood coagulation activity marker present e.g. in a urine sample, it is possible to monitor the blood coagulation activity of a patient following surgery without having to obtain a blood sample from said patient.

There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119. The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.

The disclosure features blood compatible articles and methods of making the articles. The methods include providing a substrate and forming a rough surface on the substrate. The rough surface includes a plurality of three-dimensionally curved features each having a radius of curvature of less than about 50 nm. The surface includes a sufficient concentration of features per unit area to limit blood coagulation activity on the substrate and to limit the number of platelets that adhere to the surface when the substrate is exposed to blood.

Recombinant activated protein C (APC) and APC variants with reduced anticoagulant activity were used to reduce mortality in murine models of sepsis. These models included endotoxemia and bacteremia models. We discovered that single or multiple bolus doses of APC, especially of APC variants such as RR230 / 231AA-APC, KKK192-194AAA-APC and 5A-APC (containing the combination of mutations present in the first two APC variants) given as a single bolus reduces 7-day mortality of mice given lethal doses of endotoxin. Administrations of a single bolus of 5A-APC after the initiation of sepsis also reduces mortality caused by LPS. 5A-APC with ≦8% of normal anticoagulant activity (which has reduced risk of bleeding) reduces mortality when given as two bolus administrations at 3 hours and then at 10 hours after initiation of bacterial infection, i.e. after onset of sepsis. This shows, first, that one or more bolus injections of APC or of APC variants, especially 5A-APC, can reduce mortality when given beginning hours after the onset of sepsis and, second, that it is not necessary to administer APC as a continuous infusion which is the current standard of practice because one or more bolus administrations can reduce mortality. Furthermore, dosages of approximately 0.06 to 0.4 mg / kg of APC and APC variants are identified to be sufficient to reduce mortality in sepsis.

The invention relates to a polypeptide variant Gly710Ala of a blood coagulation factor VIII or VIII a with high activity. The mutant does not destroy or inhibit the blood coagulation activity of FVIII, the blood coagulation specific activity is 1.5-2 times that of a wild type, and the mutant is more excellent in stability; the mutant obviously improves the drug efficacy of the FVIII, and has a good clinical application prospect.

The disclosure relates to a method of preventing, inhibiting, or reducing fibrosis, the incidence of fibrosis or the progression of fibrosis associated with peritoneal dialysis, during or after peritoneal is administered. More specifically, the methods relates to using intraperitoneal administration of activated protein C (APC) possessing cytoprotective or anti-inflammatory activity, to reduce the incidence or progression of fibrosis associated with peritoneal dialysis. The method is demonstrated using wild type APC and a mutant APC possessing cytoprotective or anti-inflammatory activity but lacking anti-coagulant activity.

The present invention relates to an inhibitory peptide capable of disrupting a Heparanase / Tissue Factor complex. The invention further provides methods and kits for determining heparanase procoagulant activity in a biological sample. The invention also relates to diagnostic methods for the detection and / or monitoring of a coagulation-related pathologic disorder in a mammalian subject. The invention further relates to compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. The invention still further relates to methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.

The present inventors verified the coagulation promoting effect of multispecific antigen binding molecules, said molecules replacing the function of FVIII, using blood and plasma collected from patients with FIX abnormality. As a result, it is clarified that a multispecific antigen binding molecule replacing the function of FVIII is not only usable in a method for preventing and / or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand's disease and hemophilia C caused by the dysfunction of FVIII but also usable in a method for preventing and / or treating bleeding in FIX abnormality owing to the coagulation promoting activity thereof. It is also clarified that the effect of a FIX preparation can be enhanced by the combined use of the FIX preparation with the multispecificantigen binding molecule replacing the function of FVIII and this combined use appears promising as a combination therapy showing a stable hemostatic effect.

The invention discloses a compound, its preparation method and application. The molecular formula of the compound is C 27 H 22 O 10 , the molecular weight is 506. The compound obtained by the preparation method of the present invention has high purity, 98% purity, good stability and good biological activity. Through the method of in vitro coagulation activity test, it is found that the compound has a strong inhibitory activity on platelet aggregation activated by thrombin, and has the potential to develop anticoagulant or antithrombotic drugs and medical equipment.

The invention discloses an Sj12 polypeptide from schistosoma japonicum katsurada. The polypeptide has no influence on an extrinsic coagulation system and a coagulation common path, but can interfere an endogenic coagulation system, so that the coagulation time is prolonged to a value being 10 seconds or more longer than the normal detection range; the effect of inhibiting the blood coagulation isachieved; the coagulation activity is superior to that of anticoagulant peptide in the prior art; the important anticoagulant and antithrombotic medicine development and application values are realized.

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA, but require a lower concentration of FII are described herein.